Veisblatt is a postgraduate year 2 internal medicine resident at Temple University Hospital in Philadelphia, Pennsylvania. He plans to pursue a fellowship and career in infectious diseases.
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022
Cefepimetaniborbactam may represent a safe and effective
carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
2 Clarke Drive Cranbury, NJ 08512